for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

AcelRx Pharmaceuticals Inc

ACRX.OQ

Latest Trade

1.55USD

Change

-0.06(-3.73%)

Volume

172,836

Today's Range

1.54

 - 

1.63

52 Week Range

1.49

 - 

4.08

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
1.61
Open
1.63
Volume
172,836
3M AVG Volume
17.10
Today's High
1.63
Today's Low
1.54
52 Week High
4.08
52 Week Low
1.49
Shares Out (MIL)
79.57
Market Cap (MIL)
128.11
Forward P/E
--
Dividend (Yield %)
--

Latest Developments

More

AcelRx Announces Year-End 2019 Metrics And Provides Corporate Updates

AcelRx Pharmaceuticals Reports Third Quarter Results

Acelrx Pharma Reports Q2 Loss Per Share Of $0.16

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About AcelRx Pharmaceuticals Inc

AcelRx Pharmaceuticals, Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidates include DSUVIA (known as DZUVEO in Europe) and Zalviso. Its DSUVIA is indicated for use in adults in a certified medically supervised healthcare setting, such as hospitals, surgical centers, and emergency departments, for the management of acute pain. DSUVIA is designed to provide rapid analgesia via a non-invasive route and to eliminate dosing errors associated with IV administration. Its Zalviso is a sufentanil sublingual tablet system intended for the management of moderate-to-severe acute pain in hospitalized adult patients. Zalviso consists of a pre-filled cartridge of 40 sufentanil sublingual tablets, 15 microgram (McG), delivered by the Zalviso System, a needle-free, handheld, patient-administered, pain management system.

Contact Info

351 Galveston Dr

+1.650.2163500

http://www.acelrx.com

Executive Leadership

Adrian Adams

Independent Chairman of the Board

Vincent J. Angotti

Chief Executive Officer, Director

Pamela P. Palmer

Co-Founder, Director, Chief Medical Officer

Raffi M. Asadorian

Chief Financial Officer

Badri N. Dasu

Chief Engineering Officer

Key Stats

1.80 mean rating - 5 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-0.950

2017

-1.100

2018

-0.810

2019(E)

-0.689
Price To Earnings (TTM)
--
Price To Sales (TTM)
52.79
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
-65.52
Return on Equity (TTM)
-56.23

Latest News

Latest News

FDA approves AcelRx Pharma's opioid pain drug

The U.S. Food and Drug Administration on Friday approved AcelRx Pharmaceuticals Inc's opioid-based treatment for pain to be used under strict medical supervision, with the agency's chief highlighting reasons for the approval in a rare move.

AcelRx Pharma's opioid pain drug gets U.S. FDA nod

The U.S. Food and Drug Administration on Friday approved AcelRx Pharmaceuticals Inc's opioid-based pain treatment, a fast-acting pill.

AcelRx shares surge after FDA staff says opioid safe

AcelRx Pharmaceuticals Inc's shares surged 30 percent on Wednesday after U.S. Food and Administration staff said the company's opioid treatment was safe and effective, bringing it one step closer to a marketing approval.

BRIEF-AcelRx Announces FDA Acceptance Of NDA For Dsuvia

* ACELRX PHARMACEUTICALS INC - DSUVIA PDUFA DATE SET FOR NOVEMBER 3, 2018

BRIEF-Three Arch's Shares Of AcelRx Stock Acquired In Transaction Led By Leerink Revelation Partners And Industry Ventures

* THREE ARCH'S SHARES OF ACELRX COMMON STOCK ACQUIRED IN A PRIVATE TRANSACTION LED BY LEERINK REVELATION PARTNERS AND INDUSTRY VENTURES

BRIEF-AcelRx Pharmaceuticals Reports Q1 Loss Per Share $0.23

* ACELRX PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

BRIEF-Acelrx Resubmits New Drug Application For Dsuvia

* ACELRX PHARMACEUTICALS INC - EXPECTS A SIX-MONTH REVIEW BY FDA WITH A PROJECTED PDUFA DATE IN Q4 2018

BRIEF-AcelRx Receives Positive CHMP Opinion For Dzuveo For Management Of Acute Moderate To Severe Pain In Medically Monitored Settings

* ACELRX RECEIVES POSITIVE CHMP OPINION FOR DZUVEO™ FOR MANAGEMENT OF ACUTE MODERATE TO SEVERE PAIN IN MEDICALLY MONITORED SETTINGS

BRIEF-Acelrx Announces Completion Of The Human Factors Study For Dsuvia And Confirms Plans To Resubmit NDA

* ACELRX ANNOUNCES COMPLETION OF THE HUMAN FACTORS STUDY FOR DSUVIA AND CONFIRMS PLANS TO RESUBMIT NDA IN Q2 2018 Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-AcelRx Pharma Q4 Loss Per Share $0.20

* ACELRX PHARMACEUTICALS REPORTS FOURTH QUARTER 2017 FINANCIAL RESULTS

BRIEF-AcelRX Plans To Resubmit The Dsuvia New Drug Application In Q2

* ACELRX ANNOUNCES RECEIPT OF TYPE A FDA MEETING MINUTES AND PLANS TO RESUBMIT THE DSUVIA NEW DRUG APPLICATION IN Q2 2018

BRIEF-Acelrx Pharmaceuticals posts Q3 loss of $0.28 per share

* Acelrx pharmaceuticals reports third quarter 2017 financial results

AcelRx Pharma shares sink as FDA rejects opioid painkiller

Shares of AcelRx Pharmaceuticals Inc plunged more than 60 percent on Thursday after the U.S. Food and Drug Administration declined to approve its opioid painkiller Dsuvia.

BRIEF-AcelRx Pharma receives Complete Response Letter from the FDA for Dsuvia™ NDA

* AcelRx Pharmaceuticals receives Complete Response Letter from the FDA for Dsuvia™ NDA

FDA rejects AcelRx Pharma's pain drug

U.S. health regulators did not approve AcelRx Pharmaceuticals Inc's drug Dsuvia in its present form for the management of acute pain in trauma and ambulatory settings, the company said on Thursday.

BRIEF-Acelrx pharmaceuticals says co entered into 2nd amendment with Patheon Pharma

* Acelrx Pharmaceuticals - on August 22, co entered second amendment to manufacturing services deal effective as of august 4, 2017, with Patheon Pharma

BRIEF-Acelrx Pharmaceuticals Q2 loss per share $0.29

* Acelrx Pharmaceuticals reports second quarter 2017 financial results and provides corporate update

BRIEF-AcelRx Pharmaceuticals reports successful outcome of Zalviso phase 3 IAP312 study on device functionality

* Acelrx Pharmaceuticals reports successful outcome of zalviso phase 3 IAP312 study on device functionality

BRIEF-Acelrx Pharmaceuticals appoints Raffi Asadorian CFO

* Acelrx Pharmaceuticals appoints Raffi Asadorian as chief financial officer

BRIEF-Acelrx Pharmaceuticals updates on notification from U.S. FDA

* U.S. FDA notified co that it no longer plans to hold an advisory committee meeting in connection with its review of NDA for Dsuvia

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up